SENS Jan 2025 1.500 call
| Previous close | 0.0500 |
| Open | 0.0500 |
| Bid | 0.0000 |
| Ask | 0.0500 |
| Strike | 1.50 |
| Expiry date | 2025-01-17 |
| Day's range | 0.0500 - 0.0500 |
| Contract range | N/A |
| Volume | |
| Open interest | 4k |
Business WireSenseonics Partners with Rimidi to Develop Innovative Diabetes Solution
GERMANTOWN, Md., May 09, 2024--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced a strategic partnership with Rimidi, a leading clinical management platform designed to optimize clinical workflows, enhance patient experiences, and achieve quality objectives for chronic disease management, in the development of its
ZacksClover Health Investments, Corp. (CLOV) Reports Q1 Loss, Tops Revenue Estimates
Clover Health Investments (CLOV) delivered earnings and revenue surprises of 28.57% and 9.75%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Business WireSenseonics Holdings, Inc. to Participate in Upcoming Conferences
GERMANTOWN, Md., May 02, 2024--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming RBC Capital Markets Global Healthcare Conference and the H.C. Wainwright 2nd Annual BioConnect Investor Conference, being held in New York, NY.
